Leibold, Josef http://orcid.org/0000-0003-2336-1987
Tsanov, Kaloyan M.
Amor, Corina http://orcid.org/0000-0002-7654-6216
Ho, Yu-Jui
Sánchez-Rivera, Francisco J. http://orcid.org/0000-0002-8466-8563
Feucht, Judith http://orcid.org/0000-0002-8745-1079
Baslan, Timour
Chen, Hsuan-An
Tian, Sha
Simon, Janelle
Wuest, Alexandra
Wilkinson, John E.
Lowe, Scott W. http://orcid.org/0000-0002-5284-9650
Funding for this research was provided by:
Memorial Sloan-Kettering Cancer Center (P30 CA008748)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R01CA233944)
Howard Hughes Medical Institute
EIF | Stand Up To Cancer
Deutsche Forschungsgemeinschaft (EXC2180-390900677, EXC 2180 – 390900677)
Shulamit Katzman Endowed Postdoctoral Research Fellowship
Postgraduate fellowship from La Caixa foundation and is the recipient of the Harold E. Varmus graduate student fellowship from the Gerstner Sloan Kettering graduate school
Jane Coffin Childs Memorial Fund for Medical Research
Support from the William C. and Joyce C. O'Neil Charitable Trust and the Memorial Sloan Kettering Single Cell Sequencing Initiative
Article History
Received: 22 March 2022
Accepted: 10 November 2023
First Online: 4 January 2024
Competing interests
: While not directly related to this manuscript, S.W.L. declares outside consultancy and equity for Oric Pharmaceuticals, Blueprint Medicines, Mirimus, Senecea Therapeutics, Faeth Therapeutics and PMV Pharmaceuticals; and outside consultancy (no equity) for Fate Therapeutics. J.L. has received consulting fees from Mirimus. The other authors declare no competing interests. None of these affiliations represents a competing interest with respect to the design or execution of this study or interpretation of data presented in this report.